Collegium Pharmaceutical IncNASDAQ:COLL
- LAST PRICE30.0000
- TODAY'S CHANGE (%)-0.4100 (-1.3482%)
- Bid / Lots30.0000/ 1
- Ask / Lots30.0500/ 2
- Open / Previous Close30.4000 / 30.4100
- Day Range
- 52 Week Range
- Volume251,829
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | COLL |
|---|---|---|
| 09:32 ET | 3996 | 30.355 |
| 09:33 ET | 853 | 30.35 |
| 09:35 ET | 100 | 30.405 |
| 09:37 ET | 300 | 30.42 |
| 09:39 ET | 2180 | 30.455 |
| 09:42 ET | 366 | 30.58 |
| 09:44 ET | 600 | 30.62 |
| 09:50 ET | 7066 | 30.755 |
| 09:53 ET | 100 | 30.67 |
| 09:55 ET | 100 | 30.65 |
| 09:57 ET | 100 | 30.47 |
| 10:00 ET | 300 | 30.57 |
| 10:02 ET | 300 | 30.515 |
| 10:04 ET | 100 | 30.5 |
| 10:06 ET | 2630 | 30.45 |
| 10:08 ET | 1031 | 30.45 |
| 10:09 ET | 1280 | 30.43 |
| 10:11 ET | 505 | 30.295 |
| 10:13 ET | 115 | 30.285 |
| 10:15 ET | 4682 | 30.32 |
| 10:18 ET | 2036 | 30.31 |
| 10:20 ET | 2043 | 30.29 |
| 10:22 ET | 250 | 30.29 |
| 10:24 ET | 3572 | 30.16 |
| 10:27 ET | 534 | 30.17 |
| 10:29 ET | 3806 | 30.17 |
| 10:31 ET | 200 | 30.135 |
| 10:33 ET | 2023 | 30.18 |
| 10:38 ET | 1339 | 30.255 |
| 10:42 ET | 100 | 30.27 |
| 10:45 ET | 2286 | 30.2 |
| 10:49 ET | 100 | 30.2055 |
| 10:51 ET | 100 | 30.19 |
| 10:54 ET | 100 | 30.13 |
| 10:56 ET | 2025 | 30.26 |
| 10:58 ET | 231 | 30.2507 |
| 11:00 ET | 200 | 30.27 |
| 11:03 ET | 100 | 30.25 |
| 11:09 ET | 914 | 30.32 |
| 11:14 ET | 1693 | 30.3 |
| 11:18 ET | 898 | 30.24 |
| 11:20 ET | 1300 | 30.27 |
| 11:25 ET | 300 | 30.33 |
| 11:32 ET | 129 | 30.35 |
| 11:34 ET | 1858 | 30.25 |
| 11:38 ET | 567 | 30.2498 |
| 11:39 ET | 100 | 30.25 |
| 11:41 ET | 1138 | 30.29 |
| 11:45 ET | 200 | 30.2613 |
| 11:50 ET | 3804 | 30.16 |
| 11:52 ET | 1198 | 30.14 |
| 11:54 ET | 1048 | 30.15 |
| 11:56 ET | 1194 | 30.145 |
| 11:57 ET | 200 | 30.145 |
| 11:59 ET | 100 | 30.145 |
| 12:01 ET | 2000 | 30.135 |
| 12:08 ET | 755 | 30.04 |
| 12:10 ET | 9089 | 30.03 |
| 12:12 ET | 2261 | 29.94 |
| 12:14 ET | 4122 | 30.0082 |
| 12:15 ET | 7692 | 29.99 |
| 12:17 ET | 500 | 29.96 |
| 12:19 ET | 648 | 29.96 |
| 12:24 ET | 200 | 29.94 |
| 12:26 ET | 916 | 29.9374 |
| 12:28 ET | 1542 | 29.96 |
| 12:30 ET | 1041 | 29.96 |
| 12:32 ET | 1050 | 29.88 |
| 12:33 ET | 600 | 29.87 |
| 12:35 ET | 1735 | 29.86 |
| 12:37 ET | 500 | 29.84 |
| 12:39 ET | 100 | 29.893 |
| 12:42 ET | 1000 | 29.85 |
| 12:44 ET | 580 | 29.85 |
| 12:46 ET | 400 | 29.86 |
| 12:48 ET | 200 | 29.84 |
| 12:50 ET | 534 | 29.84 |
| 12:51 ET | 200 | 29.82 |
| 12:53 ET | 300 | 29.81 |
| 12:55 ET | 300 | 29.85 |
| 12:57 ET | 500 | 29.85 |
| 01:00 ET | 2858 | 29.9 |
| 01:02 ET | 300 | 29.87 |
| 01:04 ET | 644 | 29.875 |
| 01:06 ET | 200 | 29.88 |
| 01:08 ET | 2740 | 29.86 |
| 01:09 ET | 1000 | 29.87 |
| 01:11 ET | 1000 | 29.955 |
| 01:13 ET | 6391 | 30.0199 |
| 01:15 ET | 1100 | 30.1 |
| 01:18 ET | 1011 | 30.1 |
| 01:20 ET | 555 | 30.1126 |
| 01:22 ET | 201 | 30.08 |
| 01:24 ET | 1500 | 30.035 |
| 01:26 ET | 151 | 29.99 |
| 01:29 ET | 200 | 29.99 |
| 01:31 ET | 2242 | 30.06 |
| 01:33 ET | 632 | 30.1 |
| 01:38 ET | 600 | 30.17 |
| 01:42 ET | 400 | 30.208 |
| 01:44 ET | 370 | 30.14 |
| 01:45 ET | 213 | 30.15 |
| 01:47 ET | 200 | 30.13 |
| 01:54 ET | 100 | 30.11 |
| 01:58 ET | 300 | 30.105 |
| 02:00 ET | 100 | 30.065 |
| 02:02 ET | 179 | 30.102 |
| 02:03 ET | 300 | 30.06 |
| 02:05 ET | 100 | 30.035 |
| 02:07 ET | 400 | 30 |
| 02:09 ET | 400 | 30.03 |
| 02:14 ET | 532 | 30.02 |
| 02:16 ET | 200 | 30.02 |
| 02:18 ET | 2306 | 30.07 |
| 02:23 ET | 300 | 30.1 |
| 02:34 ET | 1700 | 30.095 |
| 02:36 ET | 100 | 30.095 |
| 02:38 ET | 600 | 30.14 |
| 02:39 ET | 200 | 30.185 |
| 02:41 ET | 604 | 30.09 |
| 02:45 ET | 100 | 30.1 |
| 02:48 ET | 1304 | 30.065 |
| 02:50 ET | 318 | 30.07 |
| 02:52 ET | 500 | 30.045 |
| 02:54 ET | 1122 | 29.985 |
| 02:57 ET | 200 | 29.985 |
| 02:59 ET | 300 | 29.98 |
| 03:01 ET | 213 | 29.975 |
| 03:03 ET | 1108 | 29.97 |
| 03:06 ET | 6355 | 29.955 |
| 03:08 ET | 2844 | 30.07 |
| 03:10 ET | 500 | 30.0991 |
| 03:14 ET | 1300 | 30.01 |
| 03:15 ET | 300 | 30.03 |
| 03:17 ET | 100 | 30.005 |
| 03:19 ET | 100 | 30.01 |
| 03:24 ET | 200 | 30.01 |
| 03:26 ET | 1511 | 30.06 |
| 03:28 ET | 900 | 30.07 |
| 03:30 ET | 100 | 30.04 |
| 03:32 ET | 2284 | 30.09 |
| 03:33 ET | 400 | 30.105 |
| 03:37 ET | 200 | 30.105 |
| 03:39 ET | 800 | 30.06 |
| 03:42 ET | 800 | 30.025 |
| 03:44 ET | 700 | 30.01 |
| 03:46 ET | 300 | 30 |
Nov 12, 2024
Collegium to Participate in Upcoming Investor Conferences, from 8:01AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:01AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
DJ Collegium Pharmaceutical Taps Vikram Karnani as CEO, from 5:25PM ET on Thursday Nov 07, 2024 by Dow Jones
5:25PM ET on Thursday Nov 07, 2024 by Dow Jones*DJ Collegium Pharmaceutical 3Q EPS 27c >COLL, from 4:02PM ET on Thursday Nov 07, 2024 by Dow Jones
4:02PM ET on Thursday Nov 07, 2024 by Dow JonesCollegium Reports Record Third Quarter 2024 Financial Results, from 4:02PM ET on Thursday Nov 07, 2024 by Dow Jones
4:02PM ET on Thursday Nov 07, 2024 by Dow JonesCollegium Appoints Vikram Karnani as Chief Executive Officer, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Collegium Pharmaceutical Inc | 980.7M | 15.0x | --- |
ANI Pharmaceuticals Inc | 1.2B | -126.4x | -8.16% |
Pacira Biosciences Inc | 802.5M | -8.2x | --- |
Harmony Biosciences Holdings Inc | 1.9B | 16.0x | --- |
SNDL Inc | 525.7M | -6.6x | --- |
Tilray Brands Inc | 1.2B | -4.9x | --- |
Company Information
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.
Contact Information
- Headquarters
- 100 Technology Center DrSTOUGHTON, MA, United States 02072-4710
- Phone
- 781-713-3699
- Fax
- ---
Executives
- Chairman of the Board
- Michael Heffernan
- President, Chief Executive Officer, Director
- Vikram Karnani
- Chief Financial Officer, Executive Vice President
- Colleen Tupper
- Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
- Shirley Kuhlmann
- Executive Vice President, Chief Commercial Officer
- Scott Dreyer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $980.7M |
|---|---|
Revenue (TTM) | $599.2M |
Shares Outstanding | 32.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.81 |
EPS | $2.00 |
Book Value | $6.13 |
P/E Ratio | 15.0x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | 4.1x |
Operating Margin | 30.40% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
